Literature DB >> 14715346

Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction.

Lorenz M Fischer1, Raymond G Schlienger, Christian Matter, Hershel Jick, Christoph R Meier.   

Abstract

We explored the association between diagnosed rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) and the risk of developing a first-time acute myocardial infarction (AMI) by conducting a population-based, case-control analysis using data from the United Kingdom-based General Practice Research Database (GPRD). Among 8,688 patients with AMI and 33,329 matched controls, the adjusted odds ratio (ORs) of AMI for subjects with RA was 1.47 (95% confidence interval [CI] 1.23 to 1.76), and in subjects with both RA and diagnosed hyperlipidemia, the OR was 7.12 (95% CI 4.16 to 12.18). The risk associated with SLE was 2.67 (95% CI 1.34 to 5.34). These results underline that RA and SLE increase the risk of AMI.

Entities:  

Mesh:

Year:  2004        PMID: 14715346     DOI: 10.1016/j.amjcard.2003.09.037

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  63 in total

Review 1.  Atherosclerotic vascular disease in the autoimmune rheumatologic patient.

Authors:  Rekha Mankad
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

2.  Nephritis and the risk of acute myocardial infarction in patients with systemic lupus erythematosus.

Authors:  D K Wells; M M Ward
Journal:  Clin Exp Rheumatol       Date:  2010-05-13       Impact factor: 4.473

3.  Prevalence of dyslipidemia in Japanese patients with rheumatoid arthritis and effects of atorvastatin treatment.

Authors:  Mio Akiyama; Taro Mawatari; Yasuharu Nakashima; Hisaaki Miyahara; Hisakata Yamada; Ken Okazaki; Jun-ichi Fukushi; Masakazu Kondo; Junji Kishimoto; Chinami Hashimura; Yukihide Iwamoto
Journal:  Clin Rheumatol       Date:  2015-08-21       Impact factor: 2.980

4.  Association of systemic lupus erythematosus with angiographically defined coronary artery disease: a retrospective cohort study.

Authors:  Mala S Kaul; Sunil V Rao; Linda K Shaw; Emily Honeycutt; Stacy P Ardoin; E William St Clair
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-02       Impact factor: 4.794

Review 5.  Novel risk factors for cardiovascular disease in rheumatoid arthritis.

Authors:  Jenny Amaya-Amaya; Juan Camilo Sarmiento-Monroy; Ruben-Dario Mantilla; Ricardo Pineda-Tamayo; Adriana Rojas-Villarraga; Juan-Manuel Anaya
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

6.  Von Willebrand factor, red cell fragmentation, and disease activity in systemic lupus erythematosus.

Authors:  Rodolfo V Curiel; Rajkumari Bhagati; Lakshmi Basavaraju; Delona Norton; James Katz; Elizabeth Haile; Arthur Weinstein
Journal:  HSS J       Date:  2008-07-01

Review 7.  Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: possible interactions and implications for treatment of rheumatoid arthritis.

Authors:  Tobias Kurth; Charles H Hennekens; Julie E Buring; J Michael Gaziano
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

8.  Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intima-media thickness in female patients with active rheumatoid arthritis.

Authors:  A Ferrante; A R Giardina; F Ciccia; G Parrinello; G Licata; G Avellone; E Giardina; R Impastato; Giovanni Triolo
Journal:  Rheumatol Int       Date:  2009-12       Impact factor: 2.631

Review 9.  Pro-inflammatory genetic markers of atherosclerosis.

Authors:  Egle Incalcaterra; Giulia Accardi; Carmela Rita Balistreri; Gregorio Caimi; Giuseppina Candore; Marco Caruso; Calogero Caruso
Journal:  Curr Atheroscler Rep       Date:  2013-06       Impact factor: 5.113

Review 10.  Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.

Authors:  Sherine E Gabriel; Kaleb Michaud
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.